Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice |
| |
Authors: | Seimetz Michael Parajuli Nirmal Pichl Alexandra Veit Florian Kwapiszewska Grazyna Weisel Friederike C Milger Katrin Egemnazarov Bakytbek Turowska Agnieszka Fuchs Beate Nikam Sandeep Roth Markus Sydykov Akylbek Medebach Thomas Klepetko Walter Jaksch Peter Dumitrascu Rio Garn Holger Voswinckel Robert Kostin Sawa Seeger Werner Schermuly Ralph T Grimminger Friedrich Ghofrani Hossein A Weissmann Norbert |
| |
Affiliation: | 1 University of Giessen Lung Center (UGLC), Excellence Cluster Cardiopulmonary System (ECCPS), D-35392 Giessen, Germany 2 Max-Planck-Institute for Heart and Lung Research, D-61231 Bad Nauheim, Germany 3 Department of Cardiothoracic Surgery, University Hospital of Vienna, A-1090 Vienna, Austria 4 Biomedical Research Center (BMFZ), D-35043 Marburg, Germany |
| |
Abstract: | Chronic obstructive pulmonary disease (COPD) is one of the most common causes of death worldwide. We report in an emphysema model of mice chronically exposed to tobacco smoke that pulmonary vascular dysfunction, vascular remodeling, and pulmonary hypertension (PH) precede development of alveolar destruction. We provide evidence for a causative role of inducible nitric oxide synthase (iNOS) and peroxynitrite in this context. Mice lacking iNOS were protected against emphysema and PH. Treatment of wild-type mice with the iNOS inhibitor N(6)-(1-iminoethyl)-L-lysine (L-NIL) prevented structural and functional alterations of both the lung vasculature and alveoli and also reversed established disease. In chimeric mice lacking iNOS in bone marrow (BM)-derived cells, PH was dependent on iNOS from BM-derived cells, whereas emphysema development was dependent on iNOS from non-BM-derived cells. Similar regulatory and structural alterations as seen in mouse lungs were found in lung tissue from humans with end-stage COPD. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|